We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three ␤-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.
P
seudomonas aeruginosa has a remarkable propensity to develop antibiotic resistance (1) . ␤-Lactam resistance in P. aeruginosa is mediated through several mechanisms, including ␤-lactamase production, altered membrane permeability, MexAMexB-OprM efflux pump overexpression, and penicillin-binding protein alterations. Inducible extended-spectrum AmpC cephalosporinases may confer reduced susceptibility to all cephalosporins (2, 3) . Carbapenems are stable to AmpC cephalosporinases alone, but activity may be attenuated by combinations of Ambler class A or B ␤-lactamases, AmpC production, efflux pump upregulation, and oprD porin mutations (4, 5) . Carbapenem-resistant P. aeruginosa strains are often resistant to antipseudomonal agents such as ceftazidime, cefepime, and piperacillin-tazobactam (6) .
Avibactam, a new non-␤-lactam ␤-lactamase inhibitor, inactivates extended-spectrum ␤-lactamases (ESBLs), AmpC cephalosporinases, and class A (including Klebsiella pneumoniae carbapenemases [KPC] ), class C, and some class D ␤-lactamases (7). Ceftazidime-avibactam, an agent recently approved by the U.S. Food and Drug Administration (FDA), shows promising activity against carbapenem-resistant Enterobacteriaceae (CRE) strains, such as KPC-producing K. pneumoniae and Escherichia coli strains. Carbapenemase production is the primary determinant of carbapenem resistance among CRE strains. Ceftazidime-avibactam is less certain to be active against carbapenem-resistant P. aeruginosa, since resistance mechanisms are multifactorial. Ceftolozane, a novel cephalosporin, has less affinity for hydrolysis by Amp C cephalosporinases, is a weak substrate for drug efflux systems, and is not affected by OprD loss (4, (8) (9) (10) . The addition of the ␤-lactamase inhibitor tazobactam broadens the activity of ceftolozane to include most ESBL-producing Gram-negative bacilli (11) . In this study, we measured ceftazidime-avibactam and ceftolozane-tazobactam activities in vitro against meropenem-resistant P. aeruginosa isolates that exhibited a range of susceptibilities to ceftazidime, cefepime, and piperacillin-tazobactam.
Bloodstream (n ϭ 20) and respiratory tract (n ϭ 18) isolates were collected from unique patients at the University of Pittsburgh Medical Center. The MICs of all agents except ceftolozanetazobactam were determined in triplicate by reference broth microdilution methods (12) . Avibactam was tested at a fixed concentration (4 g/ml). Ceftolozane-tazobactam MICs were measured by Etest (bioMérieux), according to the manufacturer's recommendations. MICs were interpreted using CLSI reference breakpoints for ceftazidime, cefepime, piperacillin-tazobactam, and meropenem; isolates classified as intermediate or resistant by CLSI criteria were defined as resistant. FDA-approved susceptibility breakpoints of Յ4 g/ml and Յ8 g/ml were used for ceftolozane-tazobactam and ceftazidime-avibactam, respectively. E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used for quality controls. PCR was used to detect Amber class A (TEM, SHV, CTX-M, GES, PER, VEB, and KPC), class B (metallo-␤-lactamases VIM, IMP, and NDM), class C (CMY, MOX, FOX, ACT, and DHA), and class D (OXA) ␤-lactamases; oprD mutations were detected by PCR and DNA sequencing. The contributions of efflux to ceftazidime-avibactam and ceftolozane-tazobactam resistance were assessed with the efflux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP), at a fixed concentration of 12.5 g/ml. Comparisons involving categorical or continuous variables were made using the Fisher exact test or the Mann-Whitney test, respectively.
We tested 38 meropenem-resistant P. aeruginosa isolates ( Sixty-six percent (25/38), 55% (21/38), and 47% (18/38) of isolates were resistant to piperacillin-tazobactam, ceftazidime, and cefepime, respectively (Table 1) . Eighteen percent (7/38), 16% (6/38), and 39% (15/38) of isolates were resistant to 1, 2, or 3 of those agents, respectively. Twenty-six percent of isolates (10/ 38) were susceptible to all three agents.
The median ceftazidime-avibactam and ceftolozane-tazobactam MICs were 4 g/ml (range, 1 to Ͼ32 g/ml) and 1 g/ml (range, 0.25 to 64 g/ml), respectively (P Ͻ 0.0001). The MIC 90 s of ceftazidime-avibactam and ceftolozane-tazobactam were 8 g/ml and 4 g/ml, respectively. Ceftazidime-avibactam and ceftolozane-tazobactam MICs were strongly correlated (Spearman's r ϭ 0.91; P Ͻ 0.0001). Ceftazidime-avibactam and ceftolozanetazobactam MICs were moderately to strongly correlated with MICs for cefepime, ceftazidime, and piperacillin-tazobactam (r ranges of 0.86 to 0.93 and 0.84 to 0.98, respectively) ( Table 2 ). The median ceftazidime-avibactam and ceftolozane-tazobactam MICs were higher for isolates that were resistant to cefepime, ceftazidime, and piperacillin-tazobactam than for susceptible isolates ( Table 2 ). The median ceftazidime-avibactam and ceftolozane-tazobactam MICs increased as the number of inactive antipseudomonal drugs increased (Fig. 1) . Ceftazidime-avibactam and ceftolozane-tazobactam MICs did not correlate with meropenem MICs (r ϭ 0.06 and r ϭ 0.02, respectively; P ϭ 0.70 and P ϭ 0.91, respectively).
Eight percent (3/38) of isolates were resistant to ceftazidimeavibactam, and 8% (3/38) of isolates were resistant to ceftolozanetazobactam; 2 isolates were resistant to both agents, and 1 isolate each was resistant to one agent but not the other. Among ceftazidime-avibactam-susceptible isolates, 43% (15/35) exhibited MICs that were at the susceptibility breakpoint (8 g/ml). In contrast, 6% (2/35) of isolates that were susceptible to ceftolozanetazobactam exhibited MICs at the susceptibility breakpoint (4 g/ ml; 15/35 versus 2/35, P ϭ 0.0005). Overall, 47% (18/38) and 13% (5/38) of isolates exhibited ceftazidime-avibactam and ceftolozane-tazobactam MICs that were at or above the respective breakpoints (P ϭ 0.003).
All isolates that were resistant to either ceftazidime-avibactam or ceftolozane-tazobactam were also resistant to all 3 ␤-lactam agents. Ceftazidime-avibactam MICs were at or above the susceptibility breakpoint for 0% (0/10), 57% (4/7), 67% (4/6), and 67% (10/15) of isolates that were resistant to 0, 1, 2, and 3 ␤-lactam agents, respectively (Fig. 1 ). The corresponding rates for ceftolozane-tazobactam MICs at or above the susceptibility breakpoint were 0% (0/10 isolates), 0% (0/7), 0% (0/6), and 33% (5/15) of isolates, respectively (Fig. 1) . Isolates that were resistant to Ն2 ␤-lactams were significantly more likely to exhibit MICs at or above the breakpoint for ceftazidime-avibactam (67% [14/21] ) than that for ceftolozane-tazobactam (24% [5/21] ; P ϭ 0.03). Isolates that were resistant to 3 ␤-lactams were also more likely to exhibit MICs at or above the breakpoint for ceftazidime-avibactam (67% [10/15] ) than that for ceftolozane-tazobactam (33% [5/15] ; P ϭ 0.14).
Sixty-four percent (18/28) and 30% (3/10) of oprD mutants and wild-type isolates, respectively, were resistant to cefepime (P ϭ 0.08); 57% (16/28) and 20% (2/10) of isolates, respectively, were resistant to ceftazidime (P ϭ 0.07). There was no difference There were also no differences in ceftazidime-avibactam and ceftolozane-tazobactam MICs or resistance rates between oprD mutant and wild-type isolates.
To assess efflux, we tested all isolates that were resistant to ceftazidime-avibactam and ceftolozane-tazobactam, as well as randomly selected susceptible isolates. The median change in the ceftazidime-avibactam MIC was 0-fold (range, 0-to 2-fold) with the addition of CCCP, and median changes did not differ between resistant (n ϭ 3) and susceptible (n ϭ 4) isolates. Similarly, among ceftolozane-tazobactam-resistant (n ϭ 3) or -susceptible (n ϭ 4) isolates, MICs were not significantly reduced in combination with CCCP (median change, 0-fold [range, 0-to 2-fold]).
To our knowledge, this is the first study to compare the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against P. aeruginosa clinical isolates. Our most encouraging finding was that each agent was active against 92% of meropenemresistant P. aeruginosa isolates (35/38), including 80% of isolates (12/15) that were resistant to all three antipseudomonal ␤-lactams. Overall, at least one of the new agents retained activity against 92% (23/25), 90% (19/21) , and 89% (16/18) of isolates that were resistant to piperacillin-tazobactam, ceftazidime, and cefepime, respectively. At the same time, our data provide important cautionary notes. Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam were 8% (3/38 isolates) prior to the introduction of these agents to our hospital. Moreover, ceftazidime-avibactam and ceftolozane-tazobactam MICs correlated with each other and with ceftazidime, cefepime, and piperacillintazobactam MICs, consistent with some degree of cross-resistance. The MICs of both ceftazidime-avibactam and ceftolozanetazobactam were significantly higher as isolates became resistant to more ␤-lactams. These results corroborate recent reports of decreased susceptibility to ceftazidime-avibactam and ceftolozane-tazobactam among P. aeruginosa isolates that are resistant to other ␤-lactams, compared with isolates that are susceptible (3, (13) (14) (15) . Taken together, the data demonstrate that ceftazidimeavibactam and ceftolozane-tazobactam are important additions to the antimicrobial armamentarium, but findings suggest that the agents will need to be used judiciously to preserve their activity.
Our data suggest that ceftolozane-tazobactam may be more active than ceftazidime-avibactam against meropenem-resistant P. aeruginosa strains. Isolates were significantly more likely to exhibit MICs at or above the susceptibility breakpoint for ceftazidime-avibactam than that for ceftolozane-tazobactam. In particular, significantly greater percentages of isolates that were resistant to Ն2 antipseudomonal ␤-lactams exhibited MICs at or above the ceftazidime-avibactam breakpoint, compared with the ceftolozane-avibactam breakpoint. These results should be interpreted with the understanding that definitive breakpoint MICs have not been determined for either agent. The ceftazidime-avibactam breakpoint, for example, is based on a ceftazidime dosing regimen of 1 g every 8 h as a 30-min infusion (12) , whereas the drug has been administered as 2 g of ceftazidime and 500 mg of avibactam over 2 h in clinical trials (16) .
It is also important to appreciate that the superior performance of ceftolozane-tazobactam may reflect the particular resistance mechanisms of our P. aeruginosa isolates. The isolates in this study did not carry ESBLs or carbapenemases, which is consistent with previous reports from the United States (17, 18) , and efflux was not a significant contributor to either ceftazidime-avibactam or ceftolozane-tazobactam resistance. On the other hand, a sizeable majority of isolates exhibited oprD mutations. Avibactam restores the activity of ceftazidime against Gram-negative bacilli with resistance mediated through ESBLs, class A and some class D ␤-lactamases, and chromosomal and acquired AmpC class C enzymes (19) (20) (21) (22) . It is reasonable to hypothesize that avibactam restores susceptibility to ceftazidime through inhibition of AmpC enzymes. Indeed, a recent study showed that 91% of P. aeruginosa strains with unique AmpC sequences (31/34 isolates) demonstrated restored susceptibility to ceftazidime following the addition of avibactam (23) . Tazobactam extends the activity of ceftolozane against most class A and some class C ␤-lactamases, but the combination is less active than ceftazidime-avibactam against ESBL-or KPC-producing Gram-negative bacteria. Therefore, the isolates in this study were likely better suited to inhibition by cef- tolozane-tazobactam than ceftazidime-avibactam; results may differ at centers where ESBLs or carbapenemases are more prominent. Clinicians must understand susceptibility patterns at their institutions. Since resistance mechanisms among P. aeruginosa strains are complex and multifactorial, detailed molecular characterization of isolates should be incorporated into future studies of antimicrobial regimens (24) .
We anticipate that ceftolozane-tazobactam will be most useful at our center against infections caused by P. aeruginosa strains that are resistant to carbapenems and all ␤-lactams, as the agent is likely to be more active than ceftazidime-avibactam and less toxic than colistin or gentamicin. We anticipate that ceftazidimeavibactam will be most useful against infections caused by CRE, for which ␤-lactamases and carbapenemases are predominant resistance determinants. Indeed, ceftazidime-avibactam was more active against ESBL-and KPC-producing, carbapenem-resistant K. pneumoniae isolates from our center (MIC range, 0.125 to 4 g/ml) than reported here for meropenem-resistant P. aeruginosa isolates (MIC range, 1 to Ͼ32 g/ml) (25) . Further studies are needed to understand how ceftolozane-tazobactam and ceftazidime-avibactam can be best incorporated into clinical practice, in a manner that optimizes effectiveness while minimizing the emergence of resistance.
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